Skip to main content

Advertisement

SpringerLink
Log in

Linea guida per la terapia del sovrappeso e dell’obesità resistenti al trattamento comportamentale nella popolazione adulta con comorbilità metaboliche

Associazione Medici Endocrinologi (AME), Istituto Superiore di Sanità 2023, Associazione Italiana di Dietetica e Nutrizione Clinica (ADI), Società Italiana dell’Obesità (SIO), Società Italiana di Chirurgia dell’Obesità e delle malattie metaboliche (SICOB), Società Italiana Gastroenterologia ed Endoscopia Digestiva (SIGE)

  • LINEE GUIDA
  • Published:
L'Endocrinologo Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Bibliografia

  1. Ministero della Salute: Obesità. Ultimo aggiornamento 28 novembre 2023. www.salute.gov.it/portale/nutrizione/dettaglioContenutiNutrizione.jsp?id=5510&area=nutrizione&menu=croniche. Accessed on 27 January 2024

  2. Sharma AM, Kushner RF (2009) A proposed clinical staging system for obesity. Int J Obes (Lond) 33:289–295

    Article  CAS  PubMed  Google Scholar 

  3. Istituto Superiore di Sanità. Obesità: il rapporto 2022il rapporto 2022 dell’OMS Europa. www.epicentro.iss.it/obesita/report-obesita-oms-2022. Accessed on 27 January 2024

  4. ISTAT (2022). Sovrappeso e obesità ancora in aumento

  5. Andes LJ, Cheng YJ, Rolka DB et al. (2020) Prevalence of prediabetes among adolescents and young adults in the United States, 2005–2016. JAMA Pediatr 174:e194498

    Article  PubMed  Google Scholar 

  6. American Diabetes Association Professional Practice Committee (2022) 2. Classification and diagnosis of diabetes: standards of medical care in diabetes – 2022. Diabetes Care 45(Suppl 1):S17–S38

    Article  Google Scholar 

  7. Furtado de Souza C, Gross JL, Gerchman F, Piglet CB (2012) Pre-diabetes: diagnosis, evaluation of chronic complications, and treatment. Arq Bras Endocrinol Metabol 56:275–284

    Google Scholar 

  8. Hostalek U (2019) Global epidemiology of prediabetes – present and future perspectives. Clin Diabetes Endocrinol 5:5

    Article  PubMed  PubMed Central  Google Scholar 

  9. Schlesinger S, Neuenschwander M, Barbaresko J et al. (2022) Prediabetes and risk of mortality, diabetes-related complications and comorbidities: umbrella review of meta-analyses of prospective studies. Diabetologia 65:275–285

    Article  CAS  PubMed  Google Scholar 

  10. Menke A, Knowler WC, Cowie CC (2018) Physical and metabolic characteristics of persons with diabetes and prediabetes. In: Cowie CC, Casagrande SS, Menke A et al. (eds) Diabetes in America, 3rd edn. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD), Chapter 9

    Google Scholar 

  11. Le P, Chaitoff A, Rothberg MB et al. (2019) Trends in prevalence of nonalcoholic fatty liver disease in US adults with prediabetes. J Gen Intern Med 34:2336–2338

    Article  PubMed  PubMed Central  Google Scholar 

  12. Zupo R, Castellana F, Panza F et al. (2021) Non alcoholic fatty liver disease is positively associated with increased glycated haemoglobin levels in subjects without diabetes. J Clin Med 10:1695

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. American Diabetes Association Professional Practice Committee (2022) 3. Prevention or delay of type 2 diabetes and associated comorbidities: standards of medical care in diabetes – 2022. Diabetes Care 45(Suppl 1):S39–45

    Article  Google Scholar 

  14. AMD-SID (2018). Standard italiani per la cura del diabete mellito

  15. Istituto Superiore di Sanità. EpiCentro – L’epidemiologia per la sanità pubblica. Diabete. https://www.epicentro.iss.it/diabete. Accessed on 27 January 2024

  16. Ministero della Salute. Educazione alla corretta alimentazione. https://www.salute.gov.it/portale/nutrizione/dettaglioContenutiNutrizione.jsp?id=5566&area=nutrizione&menu=educazione. Accessed on 27 January 2024

  17. Schnurr TM, Jakupović H, Carrasquilla GD et al. (2020) Obesity, unfavourable lifestyle and genetic risk of type 2 diabetes: a case-cohort study. Diabetologia 63:1324–1332

    Article  CAS  PubMed  Google Scholar 

  18. AMD-SID (2021) La terapia del diabete mellito di tipo 2. https://www.iss.it/documents/20126/8331678/LG_379_diabete_tipo2_ed2022.pdf/9193e1fd-5d16-6baa-6513-ac385467ec64?version=1.1&t=167880775394886. Accessed on 27 January 2024

  19. Vekic J, Zeljkovic A, Stefanovic A et al. (2019) Obesity and dyslipidemia. Metabolism 92:71–81

    Article  CAS  PubMed  Google Scholar 

  20. Bamba V, Rader DJ (2007) Obesity and atherogenic dyslipidemia. Gastroenterology 132:2181–2190

    Article  CAS  PubMed  Google Scholar 

  21. Visseren FL, Mach F, Smulders YM et al. (2021) 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 42:3227–3237

    Article  PubMed  Google Scholar 

  22. Ansell BJ, Watson KE, Fogelman AM et al. (2005) High-density lipoprotein function: recent advances. J Am Coll Cardiol 46:1792–1798

    Article  CAS  PubMed  Google Scholar 

  23. Natarajan P, Ray KK, Cannon CP (2010) High-density lipoprotein and coronary heart disease: current and future therapies. J Am Coll Cardiol 55:1283–1289

    Article  CAS  PubMed  Google Scholar 

  24. Franssen R, Monajemi H, Stroes ES, Kastelein JJ (2011) Obesity and dyslipidemia. Med Clin North Am 95:893–902

    Article  CAS  PubMed  Google Scholar 

  25. Ivanova EA, Myasoedova VA, Melnichenko AA et al. (2017) Small dense low-density lipoprotein as biomarker for atherosclerotic diseases. Oxid Med Cell Longev 2017:1273042

    Article  PubMed  PubMed Central  Google Scholar 

  26. Mihaylova B, Emberson J, Blackwell L et al. (2012) The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380:581–590

    Article  CAS  PubMed  Google Scholar 

  27. Mach F, Baigent C, Catapano AL et al. (2020) 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41:111–188

    Article  PubMed  Google Scholar 

  28. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO) (2016) EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 64:1388–1402

    Article  Google Scholar 

  29. Cotter TG, Rinella M (2020) Nonalcoholic fatty liver disease 2020: the state of the disease. Gastroenterology 158:1851–1864

    Article  CAS  PubMed  Google Scholar 

  30. Bedogni G, Bellentani S, Miglioli L et al. (2006) The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 6:33

    Article  PubMed  PubMed Central  Google Scholar 

  31. European Association for the Study of the Liver (2021) EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update. J Hepatol 75:659–689

    Article  Google Scholar 

  32. Attia D, Bantel H, Lenzen H et al. (2016) Liver stiffness measurement using acoustic radiation force impulse elastography in overweight and obese patients. Aliment Pharmacol Ther 44:366–379

    Article  CAS  PubMed  Google Scholar 

  33. Chimoriya R, Piya MK, Simmons D et al. (2020) The use of two-dimensional shear wave elastography in people with obesity for the assessment of liver fibrosis in non-alcoholic fatty liver disease. J Clin Med 10:95

    Article  PubMed  PubMed Central  Google Scholar 

  34. Sterling RK, Lissen E, Clumeck N et al. (2006) Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 43:1317–1725

    Article  CAS  PubMed  Google Scholar 

  35. Kanwal F, Shubrook JH, Adams LA et al. (2021) Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. Gastroenterology 161:1657–1669

    Article  CAS  PubMed  Google Scholar 

  36. Siddiqui MS, Yamada G, Vuppalanchi R et al. for the NASH Clinical Research Network (2019) Diagnostic accuracy of noninvasive fibrosis models to detect change in fibrosis stage. Clin Gastroenterol Hepatol 17:1877–1885.e5

    Article  PubMed  PubMed Central  Google Scholar 

  37. Simon TG, Roelstraete B, Khalili H et al. (2021) Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. Gut 70:1375–1382

    Article  PubMed  Google Scholar 

  38. Tilg H, Targher G (2021) NAFLD-related mortality: simple hepatic steatosis is not as “benign” as thought. Gut 70:1212–1213

    Article  PubMed  Google Scholar 

  39. Hall JE, Carmo JM, Da Silva AA et al. (2015) Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res 116:991–1006

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Seravalle G, Grassi G (2017) Obesity and hypertension. Pharmacol Res 122:1–7

    Article  CAS  PubMed  Google Scholar 

  41. Coatmellec-Taglioni G, Ribiere C (2003) Factors that influence the risk of hypertension in obese individuals. Curr Opin Nephrol Hypertens 12:305–308

    Article  CAS  PubMed  Google Scholar 

  42. Hall JE (2003) The kidney, hypertension, and obesity. Hypertension 41:625–633

    Article  PubMed  Google Scholar 

  43. Bramlage P, Pittrow D, Wittchen HU et al. (2004) Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens 17:904–910

    Article  PubMed  Google Scholar 

  44. Droyvold WB, Midthjell K, Nilsen TI, Holmen J (2005) Change in body mass index and its impact on blood pressure: a prospective population study. Int J Obes (Lond) 29:650–655

    Article  CAS  PubMed  Google Scholar 

  45. De Pergola G, Nardecchia A, Guida P, Silvestris F (2011) Arterial hypertension in obesity: relationships with hormone and anthropometric parameters. Eur J Cardiovasc Prev Rehabil 18:240–247

    Article  PubMed  Google Scholar 

  46. Kotsis V, Tsioufis K, Antza C et al. (2018) Obesity and cardiovascular risk. A call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity. Part B: Obesity induced cardiovascular disease, early prevention strategies and future research directions. J Hypertens 36:1441–1455

    Article  CAS  PubMed  Google Scholar 

  47. Kannel WB (1995) Framingham study insights into hypertensive risk of cardiovascular disease. Hypertens Res 18:181–196

    Article  CAS  PubMed  Google Scholar 

  48. Shihab HM, Meoni LA, Chu AY et al. (2012) Body mass index and risk of incident hypertension over the life course: The Johns Hopkins Precursors Study. Circulation 126:2983–2989

    Article  PubMed  PubMed Central  Google Scholar 

  49. Mouton AJ, Li X, Hall ME, Hall JE (2020) Obesity, hypertension, and cardiac dysfunction. Novel roles of immunometabolism in macrophage activation and inflammation. Circ Res 126:789–806

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Fantin F, Giani A, Zoico E et al. (2019) Weight loss and hypertension in obese subjects. Nutrients 11:1667

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Mertens IL, Van Gaal LF (2000) Overweight, obesity, and blood pressure: The effects of modest weight reduction. Obes Res 8:270–278

    Article  CAS  PubMed  Google Scholar 

  52. Wing RR, Lang W, Wadden TA et al. (2011) Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care 34:1481–1486

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Whelton PK, Carey RM, Aronow WS et al. (2018) 2017 Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association, Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 71:e127–248

    Article  Google Scholar 

  54. Williams B, Mancia G, Spiering W et al. (2018) 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 39:3021–3104

    Article  PubMed  Google Scholar 

  55. Stevens VJ, Obarzanek E, Cook NR et al. (2001) Long-term weight loss and changes in blood pressure: results of the trials of hypertension prevention, phase II. Ann Intern Med 134:1–11

    Article  CAS  PubMed  Google Scholar 

  56. Jones DW, Miller ME, Wofford MR et al. (1999) The effect of weight loss intervention on antihypertensive medication requirements in the hypertension Optimal Treatment (HOT) study. Am J Hypertens 12:1175–1180

    Article  CAS  PubMed  Google Scholar 

  57. Kushner RF, Foster GD (2000) Obesity and quality of life. Nutrition 16:947–952

    Article  CAS  PubMed  Google Scholar 

  58. Kolotkin RL, Andersen JR (2017) A systematic review of reviews: exploring the relationship between obesity, weight loss and health-related quality of life. Clin Obes 7:273–289

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Park S (2017) Pathways linking obesity to health-related quality of life. Qual Life Res 26:2209–2218

    Article  PubMed  Google Scholar 

  60. Simon GE, Von Korff M, Saunders K et al. (2006) Association between obesity and psychiatric disorders in the US adult population. Arch Gen Psychiatry 63:824–830

    Article  PubMed  PubMed Central  Google Scholar 

  61. Onyike CU, Crum RM, Lee HB et al. (2003) Is obesity associated with major depression? Results from the third National Health and Nutrition Examination Survey. Am J Epidemiol 158:1139–1147

    Article  PubMed  Google Scholar 

  62. Grucza RA, Przybeck TR, Cloninger CR (2007) Prevalence and correlates of binge eating disorder in a community sample. Compr Psych 48:124–131

    Article  Google Scholar 

  63. Allison KC, Lundgren JD, O’Reardon JP et al. (2010) Proposed diagnostic criteria for night eating syndrome. Int J Eat Disord 43:241–247

    Article  PubMed  PubMed Central  Google Scholar 

  64. de Zwaan M, Marschollek M, Allison KC (2015) The night eating syndrome (NES) in bariatric surgery patients. Eur Eat Disord Rev 23:426–434

    Article  PubMed  Google Scholar 

  65. McCuen-Wurst C, Ruggeri M, Allison KC (2018) Disordered eating and obesity: associations between binge-eating disorder, night-eating syndrome, and weight-related comorbidities. Ann NY Acad Sci 1411:96–105

    Article  PubMed  Google Scholar 

  66. Jansen A, Houben K, Roefs A (2015) A cognitive profile of obesity and its translation into new interventions. Front Psychol 6:1807

    Article  PubMed  PubMed Central  Google Scholar 

  67. Schiff S, Amodio P, Testa G et al. (2015) Impulsivity toward food reward is related to BMI: evidence from intertemporal choice in obese and normal-weight individuals. Brain Cogn 110:112–119

    Article  PubMed  Google Scholar 

  68. Wang GJ, Volkow ND, Logan J et al. (2001) Brain dopamine and obesity. Lancet 357:354–357

    Article  CAS  PubMed  Google Scholar 

  69. Volkow ND, Wang GJ, Fowler JS, Telang F (2008) Overlapping neuronal circuits in addiction and obesity: evidence of systems pathology. Philos Trans R Soc Lond B Biol Sci 363:3191–3200

    Article  PubMed  PubMed Central  Google Scholar 

  70. Dye L, Boyle ND, Champ C, Lawton C (2017) The relationship between obesity and cognitive health and decline. Proc Nutr Soc 76:443–454

    Article  PubMed  Google Scholar 

  71. Morys F, Dadar M, Dagher A (2021) Association between midlife obesity and its metabolic consequences, cerebrovascular disease, and cognitive decline. J Clin Endocrinol Metab 106:e4260–4274

    Article  Google Scholar 

  72. Peppard PE, Young T, Palta M et al. (2000) Longitudinal study of moderate weight change and sleep-disordered breathing. JAMA 284:3015–3021

    Article  CAS  PubMed  Google Scholar 

  73. Wilson PW, D’Agostino RB, Sullivan L et al. (2002) Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 162:1867–1872

    Article  PubMed  Google Scholar 

  74. Kenchaiah S, Evans JC, Levy D et al. (2002) Obesity and the risk of heart failure. N Engl J Med 347:305–313

    Article  PubMed  Google Scholar 

  75. Wiseman M, Cannon G, Butrum R et al. (2007) Food, nutrition, physical activity, and the prevention of cancer: a global perspective. AICR, Washington

    Google Scholar 

  76. Blagojevic M, Jinks C, Jeffery A, Jordan KP (2010) Risk factors for onset of osteoarthritis of the knee in older adults: a systematic review and meta-analysis. Osteoarthr Cartil 18:24–33

    Article  CAS  Google Scholar 

  77. Chang P, Freidenberg F (2014) Obesity & GERD. Gastroenterol Clin North Am 43:161–173

    Article  PubMed  Google Scholar 

  78. Wing RR, West DS, Grady D et al. (2010) Effect of weight loss on urinary incontinence in overweight and obese women: results at 12 and 18 months. J Urol 184:1005–1010

    Article  PubMed  PubMed Central  Google Scholar 

  79. Bray GA (2004) Medical consequences of obesity. J Clin Endocrinol Metab 89:2583–2589

    Article  CAS  PubMed  Google Scholar 

  80. Bessell E, Markovic TP, Fuller NR (2021) How to provide a structured clinical assessment of a patient with overweight or obesity. Diabetes Obes Metab 23(Suppl 1):36–49

    Article  PubMed  Google Scholar 

  81. Wharton S, Lau DC, Vallis M et al. (2020) Obesity in adults: a clinical practice guideline. CMAJ 192:E875–891

    Article  Google Scholar 

  82. Busetto L, Carbonelli MG, Caretto A et al. (2022) Updating obesity management strategies: an audit of Italian specialists. Eat Weight Disord 27:2653–2663

    Article  PubMed  PubMed Central  Google Scholar 

  83. Pasquali R, Casanueva F, Haluzik M et al. (2020) European Society of Endocrinology clinical practice guideline: endocrine work-up in obesity. Eur J Endocrinol 182:G1–32

    Article  Google Scholar 

  84. Hinney A, Körner A, Fischer-Posovszky P (2022) The promise of new anti-obesity therapies arising from knowledge of genetic obesity traits. Nat Rev Endocrinol 18:623–637

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Yumuk V, Tsigos C, Fried M et al. (2015) European guidelines for obesity management in adults. Obes Facts 8:402–424. Erratum in: Obes Facts 9:64 (2016)

    Article  PubMed  PubMed Central  Google Scholar 

  86. Gruppo di studio ADI-AMD-SID “Nutrizione e diabete”. Le raccomandazioni nutrizionali 2013–2014. https://aemmedi.it/files/Linee-guida_Raccomandazioni/2013/RAC_NUTRIZIONE_DEF_2013-2014.pdf. Accessed on 27 January 2024

  87. SIO-ADI (2017) Standard Italiani per la Cura dell’Obesità 2016–2017. www.sio-obesita.org/wp-content/uploads/2017/09/STANDARD-OBESITA-SIO-ADI.pdf. Accessed on 27 January 2024

  88. Foster GD, Wyatt HR, Hill JO et al. (2010) Weight and metabolic outcomes after 2 years on a low-carbohydrate versus low-fat diet: a randomized trial. Ann Intern Med 153:147–157

    Article  PubMed  PubMed Central  Google Scholar 

  89. Shai I, Schwarzfuchs D, Henkin Y et al. for the Dietary Intervention Randomized Controlled Trial (DIRECT) Group (2008) Weight loss with a low-carbohydrate, Mediterranean. or low-fat diet. N Engl J Med 359:229–241

    Article  CAS  PubMed  Google Scholar 

  90. Yancy WS, Mayer SB, Coffman CJ et al. (2015) Effect of allowing choice of diet on weight loss. A randomized trial. Ann Intern Med 162:805–814

    Article  PubMed  PubMed Central  Google Scholar 

  91. Fidanza F (2006) La dieta di Nicotera nel 1960. Dieta mediterranea italiana di riferimento. In: De Lorenzo A, Fidanza F (eds) Dieta mediterranea italiana di riferimento. EMSI, Roma

    Google Scholar 

  92. Estruch R, Ros E (2020) The role of the Mediterranean diet on weight loss and obesity-related diseases. Rev Endocr Metab Disord 21:315–327

    Article  PubMed  Google Scholar 

  93. Kastorini CM, Milionis HJ, Esposito K et al. (2011) The effect of mediterranean diet on metabolic syndrome and its components. A meta-analysis of 50 studies and 534,906 individuals. J Am Coll Cardiol 57:1299–1313

    Article  CAS  PubMed  Google Scholar 

  94. Muscogiuri G, El Ghoch M, Colao A et al. (2021) European guidelines for obesity management in adults with a very low-calorie ketogenic diet: a systematic review and meta-analysis. Obes Facts 14:222–245

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Borrell LN, Samuel L (2014) Body mass index categories and mortality risk in US adults: the effect of overweight and obesity on advancing death. Am J Publ Health 104:512–519

    Article  Google Scholar 

  96. Piercy KL, Troiano RP, Ballard RM et al. (2018) The physical activity guidelines for Americans. JAMA 320:2020–2028

    Article  PubMed  PubMed Central  Google Scholar 

  97. Bravata DM, Smith-Spangler C, Sundaram V et al. (2007) Using pedometers to increase physical activity and improve health. A systematic review. JAMA 298:2296–2304

    Article  CAS  PubMed  Google Scholar 

  98. Swift DL, Johannsen NM, Lavie CJ et al. (2016) Effects of clinically significant weight loss with exercise training on insulin resistance and cardiometabolic adaptations. Obesity 24:812–819

    Article  CAS  PubMed  Google Scholar 

  99. Elagizi A, Kachur S, Carbone S et al. (2020) A review of obesity, physical activity, and cardiovascular disease. Curr Obes Rep 9:571–581

    Article  PubMed  Google Scholar 

  100. Swift DL, McGee JE, Earnest CP et al. (2018) The effects of exercise and physical activity on weight loss and maintenance. Prog Cardiovasc Dis 61:206–213

    Article  PubMed  Google Scholar 

  101. Douketis JD, Feightner JW, Attia J, Feldman WF (1999) Periodic health examination, 1999 update: 1. Detection, prevention and treatment of obesity. CMAJ 160:513–525

    CAS  PubMed  PubMed Central  Google Scholar 

  102. Jensen MD, Ryan DH, Apovian CM et al. (2014) 2013 AHA/ACC/TOS Guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and The Obesity Society. Circulation 129:S102–138

    Article  Google Scholar 

  103. Jastreboff AM, Aronne LJ, Ahmad NN et al. for the SURMOUNT-1 Investigators (2022) Tirzepatide once weekly for the treatment of obesity. N Engl J Med 387:205–216

    Article  CAS  PubMed  Google Scholar 

  104. Guerciolini R (1997) Mode of action of orlistat. Int J Obes Relat Metab Disord 21:S12–23

    PubMed  Google Scholar 

  105. Zhi J, Melia AT, Guerciolini R et al. (1994) Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther 56:82–85

    Article  CAS  PubMed  Google Scholar 

  106. Zhi J, Melia AT, Eggers H et al. (1995) Review of limited systemic absorption of orlistat, a lipase inhibitor, in health human volunteers. J Clin Pharmacol 35:1103–1108

    Article  CAS  PubMed  Google Scholar 

  107. Greenway FL, Whitehouse MJ, Guttadauria M et al. (2009) Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring) 17:30–39

    Article  CAS  PubMed  Google Scholar 

  108. EMA (2011) European Medicines Agency starts review of orlistat-containing medicines. Evidence relating to very rare cases of liver injury to be considered in depth. EMA/CHMP/771335/2011. www.ema.europa.eu/en/documents/press-release/european-medicines-agency-starts-review-orlistat-containing-medicines_en.pdf. Accessed on 27 January 2024

  109. Pyke C, Heller RS, Kirk RK et al. (2014) GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 155:1280–1290

    Article  PubMed  Google Scholar 

  110. Secher A, Jelsing J, Baquero AF et al. (2014) The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest 124:4473–4488

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  111. Bode B (2012) An overview of the pharmacokinetics, efficacy and safety of liraglutide. Diabetes Res Clin Pract 97:27–42

    Article  CAS  PubMed  Google Scholar 

  112. FDA (2021) FDA approves new drug treatment for chronic weight management. first since 2014. www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014. Accessed on 27 January 2024

  113. EMA (2022). Wegowy. www.ema.europa.eu/en/medicines/human/EPAR/wegovy. Accessed on 27 January 2024

  114. O’Neil PM, Birkenfeld AL, McGowan B et al. (2018) Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind. placebo and active controlled, dose-ranging, phase 2 trial. Lancet 392:637–649

    Article  PubMed  Google Scholar 

  115. Clément K, van den Akker E, Argente J et al. for the Setmelanotide POMC and LEPR Phase 3 Trial Investigators (2020) Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes Endocrinol 8:960–970

    Article  PubMed  Google Scholar 

  116. Brown RJ, Meehan CA, Cochran E et al. (2017) Effects of metreleptin in pediatric patients with lipodystrophy. J Clin Endocrinol Metab 102:1511–1519

    Article  PubMed  PubMed Central  Google Scholar 

  117. Arterburn DE, Telem DA, Kushner RF, Courcoulas AP (2020) Benefits and risks of bariatric surgery in adults: a review. JAMA 324:879–887

    Article  PubMed  Google Scholar 

  118. Consensus Development Conference Panel (1991) NIH conference: gastrointestinal surgery for severe obesity. Ann Intern Med 115:956–961

    Article  Google Scholar 

  119. Welbourn R, Hollyman M, Kinsman R et al. (2019) Bariatric surgery worldwide: baseline demographic description and one-year outcomes from the fourth IFSO global registry report 2018. Obes Surg 29:782–795

    Article  PubMed  Google Scholar 

  120. De Luca M, Piatto G, Merola G et al. (2021) IFSO update position statement on one anastomosis gastric bypass (OAGB). Obes Surg 31:3251–3278

    Article  PubMed  Google Scholar 

  121. Furbetta N, Cervelli R, Furbetta F (2020) Laparoscopic adjustable gastric banding, the past, the present and the future. Ann Transl Med 8:S4

    Article  PubMed  PubMed Central  Google Scholar 

  122. Scopinaro N, Adami GF, Marinari GM et al. (1998) Biliopancreatic diversion. World J Surg 22:936–946

    Article  CAS  PubMed  Google Scholar 

  123. Surve A, Cottam D, Medlin W et al. (2020) Long-term outcomes of primary single-anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S). Surg Obes Relat Dis 16:1638–1646

    Article  PubMed  Google Scholar 

  124. Società Italiana di Chirurgia dell’Obesità (2016) Linee Guida di Chirurgia dell’Obesità. www.sicob.org/00_materiali/linee_guida_2016.pdf. Accessed on 27 January 2024

  125. Fried M, Yumuk V, Oppert J-M et al. (2013) Interdisciplinary European Guidelines on Metabolic and Bariatric Surgery. Obes Facts 6:449–468

    Article  PubMed  PubMed Central  Google Scholar 

  126. Busetto L, Dicker D, Azran C et al. (2017) Practical recommendations of the Obesity Management Task Force of the European Association for the Study of Obesity for the post-bariatric surgery medical management. Obes Facts 10:597–632

    Article  PubMed  PubMed Central  Google Scholar 

  127. Vilarrasa N, Ruiz de Gordejuela AG, Gómez-Vaquero C et al. (2013) Effect of bariatric surgery on bone mineral density: comparison of gastric bypass and sleeve gastrectomy. Obes Surg 23:2086–2091

    Article  PubMed  Google Scholar 

  128. Osservatorio Mondiale sull’Obesità 2019

  129. Società Italiana di Chirurgia dell’Obesità (2020) Indagine conoscitiva. Anno 2019. efaidnbmnnnibpcajpcglclefindmkaj/https://www.sicob.org/00_materiali/area_medici/indagine/indagine_2019.pdf. Accessed on 27 January 2024

  130. Caleyachetty R, Thomas GN, Toulis KA et al. (2017) Metabolically healthy obese and incident cardiovascular disease events among 3.5 million men and women. J Am Coll Cardiol 70:1429–1437

    Article  PubMed  Google Scholar 

  131. Okunogbe A, Nugent R, Spencer G et al. (2022) Economic impacts of overweight and obesity: current and future estimates for 161 countries. BMJ Glob Health 7:e009773

    Article  PubMed  PubMed Central  Google Scholar 

  132. Di Bonaventura M, Nicolucci A, Meincke H et al. (2018) Obesity in Germany and Italy: prevalence, comorbidities, and associations with patient outcomes. Clinicoecon Outcomes Res 10:457–475

    Article  Google Scholar 

  133. Sbraccia P, Crialesi R, Corsaro L, Nicolucci A, Serra F (2022) 4th Italian Obesity Barometer Report. Obesity Monitor. https://www.researchgate.net/publication/368825113_ITALIAN_OBESITY_BAROMETER_REPORT_2022. Accessed on 27 January 2023

  134. Atella V, Kopinska J, Medea G et al. (2015) Excess body weight increases the burden of age associated chronic diseases and their associated health care expenditures. Aging 7:882–892

    Article  PubMed  PubMed Central  Google Scholar 

  135. European Association for the Study of the Liver (EASL) (2016) EASL Clinical practice guidelines on the prevention, diagnosis and treatment of gallstones. J Hepatol 65:146–181

    Article  Google Scholar 

  136. Mulliri A, Menahem B, Alves A, Dupont B (2022) Ursodeoxycholic acid for the prevention of gallstones and subsequent cholecystectomy after bariatric surgery: a meta-analysis of randomized controlled trials. J Gastroenterol 57:529–539

    Article  CAS  PubMed  Google Scholar 

  137. Choi JH, Lee SH, Cho IR et al. (2021) Ursodeoxycholic acid for the prevention of gallstone and subsequent cholecystectomy following gastric surgery: A systematic review and meta-analysis. J Hepatobiliary Pancreat Sci 28:409–418

    Article  PubMed  Google Scholar 

  138. Adams LB, Chang C, Pope J et al. (2016) Randomized, prospective comparison of ursodeoxycholic acid for the prevention of gallstones after sleeve gastrectomy. Obes Surg 26:990–994

    Article  PubMed  Google Scholar 

  139. Sarzani R, Castellano M, Cuspidi C et al. (2014) L’ipertensione arteriosa nel paziente obeso. Raccomandazioni congiunte 2014 della Società Italiana dell’Ipertensione Arteriosa (SIIA) e della Società Italiana dell’Obesità (SIO). Ipertensione e prevenzione cardiovascolare 21:47–105

    Google Scholar 

  140. Mantovani A, Csermely A, Petracca G et al. (2021) Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol 6:903–913

    Article  PubMed  Google Scholar 

  141. Petta S, Di Marco V, Pipitone RM et al. (2018) Prevalence and severity of nonalcoholic fatty liver disease by transient elastography. Genetic and metabolic risk factors in a general population. Liver Int 38:2060–2068

    Article  CAS  PubMed  Google Scholar 

  142. Soresi M, Noto D, Cefalu AB et al. (2013) Nonalcoholic fatty liver and metabolic syndrome in Italy: results from a multicentric study of the Italian Arteriosclerosis Society. Acta Diabetol 50:241–249

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. U.O.C. di Endocrinologia, Ospedale Regina Apostolorum, Albano Laziale (RM), Italia

    Marco Chianelli

  2. U.O.S.D. Chirurgia Bariatrica, A.O.U. Padova, Padova, Italia

    Alice Albanese

  3. Dipartimento di Scienze Medico-Chirurgiche e Medicina Traslazionale, Sapienza, Università di Roma, Roma, Italia

    Marilia Carabotti

  4. A.O.U. Sant’Andrea, Roma, Italia

    Marilia Carabotti

  5. A.O.U. di Padova, Padova, Italia

    Daniela Casarotto

  6. Centro di Nutrizione Clinica per la Ricerca e la Cura dell’Obesità e delle Malattie del Metabolismo, I.R.C.C.S. De Bellis, Castellana Grotte (BA), Italia

    Giovanni De Pergola

  7. S.C. Diabetologia, A.S.S.T. Grande Ospedale Metropolitano di Niguarda, Milano, Italia

    Olga Eugenia Disoteo

  8. S.C. Diabetologia, Dietologia, Nutrizione Clinica, A.O. S. Maria, Terni, Italia

    Ilenia Grandone

  9. Società Italiana di Medicina Generale, Macro-area metabolica (diabete, nutrizione, obesità e tiroide), Roma, Italia

    Gerardo Medea

  10. Centro di Studio e Ricerca sull’Obesità, Dipartimento di Biotecnologie Mediche e Medicina Traslazionale, Università degli Studi di Milano, Milano, Italia

    Enzo Nisoli

  11. U.O.C. Chirurgia Endocrina e Metabolica, Fondazione Policlinico Universitario Agostino Gemelli I.R.C.C.S., Roma, Italia

    Marco Raffaelli

  12. Dipartimento di Medicina – DIMED, Università di Padova, Padova, Italia

    Sami Schiff

  13. U.O.C. di Malattie Endocrine e Diabetologia, Centro di riferimento per lo studio, la diagnosi e la terapia dell’Obesità, Ospedale Sant’Anna, Como, A.S.S.T. Lariana, Como, Italia

    Federico Vignati

  14. Amici Obesi, Onlus, Milano, Italia

    Iris Zani

Authors
  1. Marco Chianelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alice Albanese
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marilia Carabotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Daniela Casarotto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Giovanni De Pergola
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Olga Eugenia Disoteo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ilenia Grandone
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Gerardo Medea
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Enzo Nisoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Marco Raffaelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Sami Schiff
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Federico Vignati
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Iris Zani
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

Commissione Linee Guida AME (Box 1)

Corresponding author

Correspondence to Marco Chianelli.

Ethics declarations

Conflitto di interesse

Tutti gli autori dichiarano di non avere conflitti di interesse.

Consenso informato

Lo studio presentato in questo articolo non ha richiesto sperimentazione umana.

Studi sugli animali

Gli autori di questo articolo non hanno eseguito studi sugli animali.

Additional information

Proposto da A. Colao.

Nota della casa editrice

Springer Nature rimane neutrale in riguardo alle rivendicazioni giurisdizionali nelle mappe pubblicate e nelle affiliazioni istituzionali.

Informazioni Supplementari

A seguire il link al materiale elettronico supplementare.

(DOC 51 kB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chianelli, M., Albanese, A., Carabotti, M. et al. Linea guida per la terapia del sovrappeso e dell’obesità resistenti al trattamento comportamentale nella popolazione adulta con comorbilità metaboliche. L'Endocrinologo 25, 84–106 (2024). https://doi.org/10.1007/s40619-024-01417-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40619-024-01417-8

Search

Navigation